Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

Subscribe To Our Latest Investor News

News Highlights
February 25, 2021

Bayer delivers robust performance despite pandemic – foundation laid for future growth

READ MORE
February 24, 2021

Bayer to Divest Environmental Science Professional Business

READ MORE
February 9, 2021

Bayer submits finerenone for marketing authorization in China

Read more
February 8, 2021

2021 ASCO GU Cancers Symposium: New data on darolutamide (Nubeqa™)

READ MORE
AD HOC

Discover Bayer’s Latest Ad Hoc Releases

READ MORE
Explore All
1 - 10of about 608 News
1 - 10of about 608 News
February 25, 2021
Fiscal 2020:
Bayer delivers robust performance despite pandemic – foundation laid for future growth
READ MORE
February 24, 2021
Bayer to Divest Environmental Science Professional Business and Further Strengthen Leadership Team of Crop Science Division
READ MORE
February 09, 2021
Not intended for U.S. and UK Media
Bayer submits finerenone for marketing authorization in China for the treatment of chronic kidney disease in type 2 diabetes
READ MORE
February 08, 2021
Not intended for U.S. and UK Media
Bayer and Orion expand development program for darolutamide in prostate cancer
READ MORE
February 08, 2021
Not intended for U.S. and UK Media
New data presented at 2021 ASCO GU Cancers Symposium add to robustness of the overall survival benefit and favorable safety profile for Nubeqa™
READ MORE
February 03, 2021
Not intended for U.S. and UK Media
Bayer receives approval for Nubeqa™ in China for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC)
READ MORE
February 03, 2021
Bayer announces agreement with plaintiffs’ counsel on class plan
READ MORE
January 20, 2021
Not intended for U.S. and UK Media
U.S. FDA approves vericiguat for patients with symptomatic chronic heart failure
READ MORE
January 13, 2021
Not intended for U.S. and UK Media - Virtual Bayer Pharma Media Day:
Bayer transforms pharma business through breakthrough innovation in healthcare
READ MORE
January 12, 2021
Not intended for U.S. and UK Media
U.S. FDA grants Priority Review to New Drug Application for finerenone to treat patients with chronic kidney disease and type 2 diabetes
READ MORE
1 - 10of about 608 News
1 - 10of about 608 News